bioavailability, biobeschikbaarheid absorption, absorptie
Conditions
Interventions
Study I:
Intake of
1. milk
2. Zn-fortified milk
3. water + Zn supplement
4. raw milk
All test meals are extrinsically labelled with 67Zn.
Study II:
Intake of
1. intrinsically 67Zn label
Sponsors
Wageningen University
Division of Human Nutrition
Eligibility
Inclusion criteria
Inclusion criteria: • Female • Age between 18-30 years of age (boundaries included) • Body Mass Index (BMI) between 19-25 kg/m2 (boundaries included) • Body weight between 60-70 kg (boundaries included) • No mineral and vitamin supplements two weeks prior to the 1st test meal and during the whole duration of the study • Willing to abstain from blood donation during the study • Voluntary participation • Signed informed consent • Willing to comply with the study procedures
Exclusion criteria
Exclusion criteria: • Any metabolic, gastrointestinal, inflammatory or chronic disease or disorder (such as diabetes, anaemia, hepatitis, hypertension, cancer or cardiovascular diseases; according to the subjects own statement) • Continuous/long-term medication during the whole study (except for contraceptives) • Mineral or vitamin supplements during the 2 weeks prior to 1st test meal • Lactose intolerance • Alcohol consumption > 21 glasses per week • Bad venous access • Reported weight loss or gain of > 2 kg in the last month before screening • Reported strictly prescribed diet, vegetarian, vegan or macrobiotic • Smoking • Pregnant or lactating or the wish to become pregnant in the study period (a pregnancy test will be done at screening) • Lack of safe contraception • Earlier participation in any nutrition study using Zn stable isotopes as well as participation in any other clinical study within the last 30 days and during this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fractional absorption of Zn, as measured from isotope ratios in urine samples. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Zn status in blood • Inflammation markers(C-reactive protein (CRP) and á-glycoprotein (AGP)) in blood. | — |
Contacts
Public ContactEsther Boelsma
Wageningen UR Food & Biobased Research Bornse Weilanden 9
Outcome results
None listed